Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In
Optimize patients' access to health care through evidence - worldwide

Outcomes research

Outcomes research pertains to the effect of healthcare interventions in economic, clinical or humanistic terms. The goal of outcomes research is to inform decision makers about the end results of a healthcare intervention. The target audience of outcomes research can be anyone who participates in healthcare, like: 
·         Patients
·         Clinicians
·         Insurers
·         Hospital management
·         Pharmacists
·         Policy makers
Our services in the field of outcomes research are very diverse and range from designing and validating measurement tools to conducting observational studies in the field.
Use available scientific evidence efficiently without the need to perform new trials. Our advanced evidence synthesis techniques include (Bayesian) network meta-analyses, indirect treatment comparisons, and advanced statistical analyses. 
Many health authorities require that health benefits are expressed as quality-adjusted life years (QALY’s). We are very familiar with the complexities of measuring health-related quality-of-life, and have experience with both generic and disease specific questionnaires  like EQ-5D, SF-36, EORTC and MADRS.
When applied appropriately, Patient Reported Outcomes (PRO) can substantiate labeling claims with the FDA/EMEA. PRO’s are collected from patients themselves, and may concern anything that involves a patient’s experience, preference or value.
Medical charts are valuable sources of real-life data on topics like disease epidemiology, treatment patterns, survival and health outcomes. We collaborate with Medical Data Analytics to perform efficient and accurate chart studies.   
From information about claims made to health care insurance companies on behalf of patients, we extract data as a source of information for epidemiological research, costing research, outcomes research and cost-effectiveness research.
We offer consultancy in early stages of clinical development to integrate health economics in the clinical trial design. In addition, we design the set-up for separate pharmacoeconomic trials in which all outcomes that are relevant to evaluate a product’s cost-effectiveness are collected within one empirical study.